* To pay $1.18 bln in cash, issue 40 million new shares * Deal will make Hikma sixth biggest U.S. generics provider * Targeting 2017 revenue of $725 mln-$775 mln from units * Shares surge in London (Adds Hikma CEO, analyst comments) By Aastha Agnihotri and Roshni MenonRead more
(ShareCast News) - The selling pressure on stocks abated as investors waited on the US Federal Reserve's policy announcement on Wednesday, but worries regarding the outlook for China, Greece and the possibility of interest rate increases were still very much on investors' minds. As of 08:47 the FTSE
Read more(ShareCast News) - Drug developer Hikma Pharmaceuticals signed a deal to buy two firms from Boehringer Ingelheim in transactions worth a total of $2.25bn. FTSE 100 listed Hikma planned to buy Roxane Laboratories and associated company Boehringer Ingelheim Roxane in a cash and shares deal that would
Read more** Hikma rises 6.7 pct after agreeing to buy Boehringer's specialty generics business for $2.65 bln in cash ** Valuation based on new Hikma shares priced at £23.50 ** Best day for stock since January 2015 ** Among top risers and most traded by average volumes on Stoxx 600
July 28 (Reuters) - Hikma Pharmaceuticals Plc said it would buy German drugmaker Boehringer Ingelheim's U.S. specialty generic drugs business for about $2.65 billion in cash and stock to bolster its presence in the United States. Hikma said it will pay about $1.18 billion in cash and issue
Read more